Subsidy Information and Financing Scheme SDLCalfactant Intratracheal Suspension 105 mg/3 mL, 210 mg/6 mL
Drug Guidance for Subsidy 01/09/2020 Pulmonary surfactant for treating respiratory distress syndrome in premature infants The Ministry of Health’s Drug Advisory Committee has recommended: Calfactant 105 mg/3 ml and... See all × 01/09/2020 Pulmonary surfactant for treating respiratory distress syndrome in premature infants The Ministry of Health’s Drug Advisory Committee has recommended: Calfactant 105 mg/3 ml and 210 mg/6 ml and poractant alfa 120 mg/1.5 ml intratracheal suspension vials for treating respiratory distress syndrome in premature infants. Subsidy status RCalfactant 105 mg/3 ml and 210 mg/6 ml, and poractant alfa 120 mg/1.5 ml intratracheal suspension vials are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. NRSDL does not apply to beractant 200 mg/8 ml vial. RPoractant alfa does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before poractant alfa is administered, it is important to consider the availability of other suitable registered alternatives and inform the parent(s) or carer of the infant that the product is unregistered.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Infasurf Intratracheal Suspension 105 mg/3 mL KK Women's and Children's Hospital Singapore General Hospital
INTRATRACHEAL Select a brand starting with the letter: I INFASURF INTRATRACHEAL SUSPENSION 35MG/ML [SIN14333P]